SCHEMBL1879898

SCHEMBL1879898

COC(=O)c1ccc(COc2cccc(-c3nc(N)nc4ccc(Cl)cc34)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.50
KCNH2 Q12809 1/20 0.50
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.47
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
RXRG P48443 1/20 0.47
BACE1 P56817 1/20 0.46
DHFR P00374 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
NR1H2 P55055 1/20 0.46
ADORA2A P29274 1/20 0.45
NR4A2 P43354 1/20 0.44
HSP90AB1 P08238 1/20 0.44
SLC9A3 P48764 3/20 0.44
PLA2G2A P14555 1/20 0.44
MAOA P21397 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1881261 0.92 MRGPRX4 (0.53) BACE1DHFRNPC1RAB9AADORA2A
SCHEMBL1883379 0.91 RXRA (0.58) KDM4EALDH1A1MAPTHPGDRXRA
SCHEMBL1879985 0.87 BACE1 (0.55) CYP3A4RXRARXRBRXRGBACE1
SCHEMBL1876600 0.86 HSP90AB1 (0.62) KDM4EALDH1A1MAPTHPGDBACE1
SCHEMBL1883217 0.85 DHFR (0.60) CYP3A4KCNH2MAPTHPGDDHFR
SCHEMBL1880116 0.84 MRGPRX4 (0.56) BACE1NR4A2EGLN1
SCHEMBL1877697 0.84 BACE1 (0.52) KDM4EALDH1A1MAPTBACE1DHFR
SCHEMBL1881986 0.82 DHFR (0.55) BACE1DHFRADORA2ANR4A2HSP90AB1
SCHEMBL1879428 0.82 BACE1 (0.48) KDM4EALDH1A1MAPTHPGDBACE1
SCHEMBL1879206 0.81 BACE1 (0.49) BACE1DHFRNR1H2ADORA2AHSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947696-B2 heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases MERCK PATENT GMBH (DE) 2011-05-24 US claimed
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2008-09-04 US claimed
CN-101180278-A 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH (DE) 2008-05-14 CN claimed
US-7947696-B2 heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases MERCK PATENT GMBH (DE) 2011-05-24 US disclosed
CN-101180278-B 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH 2011-05-04 CN disclosed
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2008-09-04 US disclosed
CN-101180278-A 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH (DE) 2008-05-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators HSP90AB2P, HSP90AB1, HSP90AA1 CYP3A4 2509/4885KCNH2 4203/4885KDM4E 2754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.